^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    BCL2A1 (BCL2 Related Protein A1)

    i
    Other names: BCL2A1, BCL2 Related Protein A1, Hemopoietic-Specific Early Response Protein, Bcl-2-Related Protein A1, Bcl-2-Like Protein 5, Protein BFL-1, Bcl2-L-5, BCL2L5, HBPA1, BFL1, GRS, Hematopoietic BCL2-Related Protein A1, Protein GRS, ACC-1, ACC-2, ACC1, ACC2
    8d
    Expression Levels of TGM2, ANKRD55, BCL2A1, CASP5, GRB10, TOP2A, and KLRD1 Genes in Peripheral Blood Mononuclear Cells of Sepsis Patients and Their Diagnostic Value for Acute Lung Injury: A Prospective Observational Cohort Study (ChiCTR2500112744)
    P=N/A, N=120, Not yet recruiting, Yichang Central People's Hospital; Yichang Central People's Hospital
    New trial
    |
    BCL2A1 (BCL2 Related Protein A1)
    11d
    Dihydroartemisinin Promotes N1 Polarization of Tumor-Associated Neutrophils and Enhances Their Anti-Tumor Activity via Hub Gene Modulation. (PubMed, Pharmaceuticals (Basel))
    Functional assays demonstrated that DHA-treated cells exhibited increased secretion of TNF, IL1β, ROS, and PD-L1, accompanied by enhanced cytotoxic activity against hepatocellular carcinoma cells in a co-culture system. These findings reveal the molecular mechanisms underlying TAN polarization, and establish DHA as a potent immunomodulatory agent capable of reshaping TANs toward an anti-tumor phenotype.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • BCL2A1 (BCL2 Related Protein A1) • IL1B (Interleukin 1, beta) • CEACAM8 (CEA Cell Adhesion Molecule 8) • CXCL16 (C-X-C Motif Chemokine Ligand 16) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA) • SOCS3 (Suppressor Of Cytokine Signaling 3)
    1m
    CK2 inhibitor, CX-4945, enhances BH3 priming and promotes apoptosis of venetoclax-resistant AML by targeting antiapoptotic proteins. (PubMed, bioRxiv)
    CX-4945 (silmitasertib) is being tested in several early-phase clinical trials against adult and pediatric cancers. These preclinical results support the use of CX-4945 in combination with VEN to overcome resistance to apoptosis and re-sensitize VR-AML to chemotherapy.
    Journal • IO biomarker
    |
    MCL1 (Myeloid cell leukemia 1) • CD38 (CD38 Molecule) • BCL2L1 (BCL2-like 1) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD34 (CD34 molecule) • BCL2A1 (BCL2 Related Protein A1) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Venclexta (venetoclax) • silmitasertib (CX-4945)
    1m
    Expression of the CXCR4 S338X Variant Improves Anti-Leukemia Efficacy of Anti-CD19 CAR-T Cells. (PubMed, Cancer Sci)
    Furthermore, CAR19/CXCR4S338X-T cells demonstrated significantly improved migration to and retention in the BM accompanied by increased CD45RA+CCR7+ memory T cell populations, which correlated with enhanced anti-leukemic effects following injection into B-ALL-bearing mice. This study offers a potentially effective strategy to improve the functionality and durability of CAR-T cell responses in hematological malignancies.
    Journal • IO biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CDK6 (Cyclin-dependent kinase 6) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CCR7 (Chemokine (C-C motif) receptor 7) • BCL2A1 (BCL2 Related Protein A1) • GZMB (Granzyme B)
    2ms
    Canady Helios Cold Plasma Induces Non-Thermal (24 °C), Non-Contact Irreversible Electroporation and Selective Tumor Cell Death at Surgical Margins. (PubMed, Cancers (Basel))
    This study demonstrates CHCP as a non-thermal (24 °C), non-contact plasma-based IRE platform which induces controlled membrane permeabilization and selective cancer cell death. CHCP offers a translational strategy to eradicate residual tumor cells at the surgical margins, and prevent local recurrence, positioning it as a versatile adjunct in precision surgical oncology.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BCL2A1 (BCL2 Related Protein A1)
    |
    HER-2 negative
    2ms
    Linking the Warburg effect to endometrial receptivity: metabolic parallels in embryo implantation. (PubMed, Front Cell Dev Biol)
    Targeting this shared metabolic-immune-hormonal axis holds immense potential for developing innovative strategies (e.g., metabolic modulators, refined TCM approaches) to improve ER, enhance embryo implantation rates in infertility (including IVF) and recurrent miscarriage, ultimately advancing global reproductive health. Further research is needed to validate core mechanisms.
    Review • Journal
    |
    BCL2A1 (BCL2 Related Protein A1) • TGFB1 (Transforming Growth Factor Beta 1) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3) • SLC2A1 (Solute Carrier Family 2 Member 1)
    2ms
    Gene Expression Profiling Provides an Improved Characterization of CD79B-Mutated Diffuse Large B-Cell Lymphomas. (PubMed, J Pers Med)
    TP53 mutation showed an association with poorer overall survival in a secondary analysis, consistent with prior reports, while survival by CD79B/MYD88 mutation status and the differentially expressed genes showed no significant differences in this cohort. In conclusion, the current study identified novel up-regulated genes in CD79B-mutated DLBCLs beyond NF-κB pathway signaling, which may contribute to a better definition of potential therapeutic targets and further improves the characterization of this distinct and aggressive DLBCL subgroup.
    Journal
    |
    TP53 (Tumor protein P53) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • RUNX1 (RUNX Family Transcription Factor 1) • CD79B (CD79b Molecule) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CARD11 (Caspase Recruitment Domain Family Member 11) • IL10 (Interleukin 10) • CD14 (CD14 Molecule) • PIM1 (Pim-1 Proto-Oncogene) • BCL2A1 (BCL2 Related Protein A1) • GZMB (Granzyme B) • IL7 (Interleukin 7) • RASGRF1 (Ras Protein Specific Guanine Nucleotide Releasing Factor 1) • AFDN (Afadin, Adherens Junction Formation Factor) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1) • WNT11 (Wnt Family Member 11)
    |
    TP53 mutation
    3ms
    Development of a single-cell derived MDSCs signature score for prognostic risk stratification and therapeutic decision guidance in breast cancer. (PubMed, Transl Oncol)
    This investigation marks the initial systematic characterization of a new MDSCs gene signature in breast cancer, alongside the establishment of an MDSCs-associated marker scoring framework with multi-aspect clinical translation capability, thereby linking MDSCs fundamental biology to precision oncology in this cancer type.
    Journal • IO biomarker
    |
    BCL2A1 (BCL2 Related Protein A1) • RNASE1 (Ribonuclease A Family Member 1) • SERPINA1 (Serpin Family A Member 1)
    3ms
    Integrating computational pathology and multi-transcriptomics to characterize glioblastoma heterogeneity and identify prognostic biomarkers. (PubMed, Hum Pathol)
    Integration of computational pathology and multi-transcriptomic data identified BCL2A1+ monocytes as drivers of angiogenesis and progression. This approach offers a prognostic tool and potential therapeutic targets for GBM.
    Journal
    |
    BCL2A1 (BCL2 Related Protein A1)
    3ms
    Intratumoral SPP1+BCL2A1+ Tumor-Associated Macrophages Predict Poor Response to PD1 Blockade. (PubMed, Diagnostics (Basel))
    Our findings identify SPP1+BCL2A1+ TAMs as a poor prognostic biomarker in HCC patients undergoing ICB therapy. By promoting an immunosuppressive microenvironment, SPP1+BCL2A1+ TAMs, which are survival-advantaged, may represent both a predictive marker and a potential therapeutic target to enhance the efficacy of immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • PD-1 (Programmed cell death 1) • SPP1 (Secreted Phosphoprotein 1) • BCL2A1 (BCL2 Related Protein A1)
    3ms
    Exploring the prognostic value of T cell exhaustion and mitochondrial dysfunction related genes in breast cancer through bioinformatics analysis and RT-qPCR validation. (PubMed, Clin Exp Med)
    The accurate risk model stratified patients: high-risk correlated with suppressed immunity (p < 2.2e-16), elevated TIDE (p = 5.4e-14), and higher CI.1040 IC50 (cor = 0.63, p < 0.0001)...Risk score, age, race, N/M-stage were independent factors. Seven prognostic genes effectively predicted BRCA prognosis with independent prognostic factors.
    Journal • BRCA Biomarker
    |
    CD74 (CD74 Molecule) • BRCA (Breast cancer early onset) • BCL2A1 (BCL2 Related Protein A1) • GZMB (Granzyme B) • PPP1R15A (Protein Phosphatase 1 Regulatory Subunit 15A) • IRF7 (Interferon Regulatory Factor 7) • MTHFD2 (Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2)
    |
    CI-1040
    5ms
    Identification and Validation of Mitochondria-Related Genes for Diagnosis of Early-Stage Sepsis. (PubMed, Ann Clin Lab Sci)
    These findings suggest that mitochondrial dysfunction plays a critical role in sepsis progression, and the identified genes may serve as biomarkers for early diagnosis and targeted treatment, potentially improving patient outcomes.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2A1 (BCL2 Related Protein A1) • ARG2 (Arginase 2) • IFI27 (Interferon Alpha Inducible Protein 27)